Data Insights

Retlirafusp alfa by Jiangsu Hengrui Medicine for Squamous Non-Small Cell Lung Cancer: Likelihood of Approval

Retlirafusp alfa is under clinical development by Jiangsu Hengrui Medicine and currently in Phase II for Squamous Non-Small Cell Lung...

Likelihood of Approval and Phase Transition Success Rate Model - Retlirafusp Alfa in Squamous Non-Small Cell Lung Cancer

Data Insights

Retlirafusp alfa by Jiangsu Hengrui Medicine for Bile Duct Cancer (Cholangiocarcinoma): Likelihood of Approval

Retlirafusp alfa is under clinical development by Jiangsu Hengrui Medicine and currently in Phase II for Bile Duct Cancer (Cholangiocarcinoma)....

Likelihood of Approval and Phase Transition Success Rate Model - Retlirafusp Alfa in Bile Duct Cancer (Cholangiocarcinoma)

Data Insights

Retlirafusp alfa by Jiangsu Hengrui Medicine for Hepatocellular Carcinoma: Likelihood of Approval

Retlirafusp alfa is under clinical development by Jiangsu Hengrui Medicine and currently in Phase II for Hepatocellular Carcinoma. According to...

Likelihood of Approval and Phase Transition Success Rate Model - Retlirafusp Alfa in Hepatocellular Carcinoma

Data Insights

Retlirafusp alfa by Jiangsu Hengrui Medicine for Melanoma: Likelihood of Approval

Retlirafusp alfa is under clinical development by Jiangsu Hengrui Medicine and currently in Phase II for Melanoma. According to GlobalData,...

Likelihood of Approval and Phase Transition Success Rate Model - Retlirafusp Alfa in Melanoma

Data Insights

Trastuzumab rezetecan by Jiangsu Hengrui Medicine for Metastatic Colorectal Cancer: Likelihood of Approval

Trastuzumab rezetecan is under clinical development by Jiangsu Hengrui Medicine and currently in Phase I for Metastatic Colorectal Cancer. According...

Likelihood of Approval and Phase Transition Success Rate Model - Trastuzumab Rezetecan in Metastatic Colorectal Cancer

Data Insights

Ivarmacitinib sulfate by Jiangsu Hengrui Medicine for Graft Versus Host Disease (GVHD): Likelihood of Approval

Ivarmacitinib sulfate is under clinical development by Jiangsu Hengrui Medicine and currently in Phase I for Graft Versus Host Disease...

Likelihood of Approval and Phase Transition Success Rate Model - Ivarmacitinib Sulfate in Graft Versus Host Disease (GVHD)

Data Insights

SHRA-1904 by Jiangsu Hengrui Medicine for Gastric Cancer: Likelihood of Approval

SHRA-1904 is under clinical development by Jiangsu Hengrui Medicine and currently in Phase II for Gastric Cancer. According to GlobalData,...

Likelihood of Approval and Phase Transition Success Rate Model - SHRA-1904 in Gastric Cancer

Data Insights

SHRA-1904 by Jiangsu Hengrui Medicine for Gastroesophageal (GE) Junction Carcinomas: Likelihood of Approval

SHRA-1904 is under clinical development by Jiangsu Hengrui Medicine and currently in Phase II for Gastroesophageal (GE) Junction Carcinomas. According...

Likelihood of Approval and Phase Transition Success Rate Model - SHRA-1904 in Gastroesophageal (GE) Junction Carcinomas

Data Insights

HRS-7085 by Jiangsu Hengrui Medicine for Inflammatory Bowel Disease: Likelihood of Approval

HRS-7085 is under clinical development by Jiangsu Hengrui Medicine and currently in Phase I for Inflammatory Bowel Disease. According to...

Likelihood of Approval and Phase Transition Success Rate Model - HRS-7085 in Inflammatory Bowel Disease

Data Insights

SHRA-1921 by Jiangsu Hengrui Medicine for Solid Tumor: Likelihood of Approval

SHRA-1921 is under clinical development by Jiangsu Hengrui Medicine and currently in Phase I for Solid Tumor. According to GlobalData,...

Likelihood of Approval and Phase Transition Success Rate Model - SHRA-1921 in Solid Tumor

Data Insights

SHRA-1904 by Jiangsu Hengrui Medicine for Pancreatic Cancer: Likelihood of Approval

SHRA-1904 is under clinical development by Jiangsu Hengrui Medicine and currently in Phase II for Pancreatic Cancer. According to GlobalData,...

Likelihood of Approval and Phase Transition Success Rate Model - SHRA-1904 in Pancreatic Cancer

Data Insights

SHRA-1904 by Jiangsu Hengrui Medicine for Solid Tumor: Likelihood of Approval

SHRA-1904 is under clinical development by Jiangsu Hengrui Medicine and currently in Phase II for Solid Tumor. According to GlobalData,...

Likelihood of Approval and Phase Transition Success Rate Model - SHRA-1904 in Solid Tumor

Data Insights

Camrelizumab by Jiangsu Hengrui Medicine for Triple-Negative Breast Cancer (TNBC): Likelihood of Approval

Camrelizumab is under clinical development by Jiangsu Hengrui Medicine and currently in Phase III for Triple-Negative Breast Cancer (TNBC). According...

Likelihood of Approval and Phase Transition Success Rate Model - Camrelizumab in Triple-Negative Breast Cancer (TNBC)

Data Insights

Camrelizumab by Jiangsu Hengrui Medicine for Gastric Cancer: Likelihood of Approval

Camrelizumab is under clinical development by Jiangsu Hengrui Medicine and currently in Phase II for Gastric Cancer. According to GlobalData,...

Likelihood of Approval and Phase Transition Success Rate Model - Camrelizumab in Gastric Cancer

Data Insights

Famitinib by Jiangsu Hengrui Medicine for Hepatocellular Carcinoma: Likelihood of Approval

Famitinib is under clinical development by Jiangsu Hengrui Medicine and currently in Phase II for Hepatocellular Carcinoma. According to GlobalData,...

Likelihood of Approval and Phase Transition Success Rate Model - Famitinib in Hepatocellular Carcinoma

Data Insights

Famitinib by Jiangsu Hengrui Medicine for Renal Cell Carcinoma: Likelihood of Approval

Famitinib is under clinical development by Jiangsu Hengrui Medicine and currently in Phase II for Renal Cell Carcinoma. According to...

Likelihood of Approval and Phase Transition Success Rate Model - Famitinib in Renal Cell Carcinoma

Data Insights

Famitinib by Jiangsu Hengrui Medicine for Triple-Negative Breast Cancer (TNBC): Likelihood of Approval

Famitinib is under clinical development by Jiangsu Hengrui Medicine and currently in Phase III for Triple-Negative Breast Cancer (TNBC). According...

Likelihood of Approval and Phase Transition Success Rate Model - Famitinib in Triple-Negative Breast Cancer (TNBC)

Data Insights

Famitinib by Jiangsu Hengrui Medicine for Anaplastic Thyroid Cancer: Likelihood of Approval

Famitinib is under clinical development by Jiangsu Hengrui Medicine and currently in Phase II for Anaplastic Thyroid Cancer. According to...

Likelihood of Approval and Phase Transition Success Rate Model - Famitinib in Anaplastic Thyroid Cancer

Data Insights

Famitinib by Jiangsu Hengrui Medicine for Thyroid Cancer: Likelihood of Approval

Famitinib is under clinical development by Jiangsu Hengrui Medicine and currently in Phase II for Thyroid Cancer. According to GlobalData,...

Likelihood of Approval and Phase Transition Success Rate Model - Famitinib in Thyroid Cancer

Data Insights

Famitinib by Jiangsu Hengrui Medicine for Medullary Thyroid Cancer: Likelihood of Approval

Famitinib is under clinical development by Jiangsu Hengrui Medicine and currently in Phase II for Medullary Thyroid Cancer. According to...

Likelihood of Approval and Phase Transition Success Rate Model - Famitinib in Medullary Thyroid Cancer